08:25 AM EDT, 09/18/2024 (MT Newswires) -- TG Therapeutics ( TGTX ) said Wednesday that updated data from a phase 3b trial showed that rapid 30-minute infusions of BRIUMVI (ublituximab) are well tolerated in patients suffering from relapsing forms of multiple sclerosis.

The trial demonstrated that 450 mg of BRIUMVI administered in 30 minutes at week 24 was completed without interruption in all patients, with infusion-related reactions limited to Grade 1, TG Therapeutics ( TGTX ) said.

The data also confirmed that BRIUMVI can be safely given as a 1-hour infusion, with 97% of these infusions completed without issues, it added.

Shares of the company were up nearly 4% in recent Wednesday premarket activity.

Price: 26.06, Change: +0.98, Percent Change: +3.91